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Background: Dent disease 1 represents a hereditary disorder of renal tubular epithelial function associated with
mutations in the CLCN5 gene that encoded the ClC-5 Cl-/H+ antiporter. All of the reported disease-causing mutations
are localized in the coding region except for one recently identified in the 5’UTR region of a single patient. This finding
highlighted the possible role for genetic variability in this region in the pathogenesis of Dent disease 1.
The structural complexity of the CLCN5 5’UTR region has not yet been fully characterized. To date 6 different
5’ alternatively used exons - 1a, 1b, 1b1 and I-IV with an alternatively spliced exon II (IIa, IIb) - have been described, but
their significance and differential expression in the human kidney have not been investigated. Therefore our aim was
to better characterize the CLCN5 5’UTR region in the human kidney and other tissues.
Methods: To clone more of the 5’ end portion of the human CLCN5 cDNA, total human kidney RNA was utilized as
template and RNA ligase-mediated rapid amplification of cDNA 5’ ends was applied.
The expression of the different CLCN5 isoforms was studied in the kidney, leucocytes and in different tissues by
quantitative comparative RT/PCR and Real -Time RT/PCR.
Results: Eleven transcripts initiating at 3 different nucleotide positions having 3 distinct promoters of varying strength
were identified. Previously identified 5’UTR isoforms were confirmed, but their ends were extended. Six additional
5’UTR ends characterized by the presence of new untranslated exons (c, V and VI) were also identified. Exon c
originates exon c.1 by alternative splicing. The kidney uniquely expresses all isoforms, and the isoform containing exon
c appears kidney specific. The most abundant isoforms contain exon 1a, exon IIa and exons 1b1 and c. ORF analysis
predicts that all isoforms except 3 encode for the canonical 746 amino acid ClC-5 protein.
Conclusions: Our results confirm the structural complexity of the CLCN5 5’UTR region. Characterization of this crucial
region could allow a clear genetic classification of a greater number of Dent disease patients, but also provide the basis
for highlighting some as yet unexplored functions of the ClC-5 proton exchanger.
Keywords: Dent disease, CLCN5 gene, 5’UTR isoforms, mRNA variant, Gene expressionBackground
Dent disease 1 (OMIM 300009) is an X-linked recessive
disorder of renal tubular epithelial function, associated
with genetic variation of the CLCN5 gene that encodes
the ClC-5 Cl−/H+ antiporter. The disease is character-
ized by low-molecular-weight proteinuria, hypercalciu-
ria, nephrocalcinosis, nephrolithiasis and one or several* Correspondence: enrica.tosetto@unipd.it
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unless otherwise stated.features of proximal tubular dysfunction (glycosuria, ami-
noaciduria, and phosphaturia, etc.) [1]. ClC-5 is expressed
in the kidney, particularly in proximal tubular cells and in-
tercalated collecting duct cells. The human CLCN5 gene,
spanning about 170 kb of genomic DNA on chromosome
Xp11.23/p11.22, consists of 17 exons including 11 coding
exons (2-12) and 6 different 5′ alternatively used exons
(5′UTR), some remaining untranslated [1-4]. Transcripts
including the untranslated exon 1a (NM_000084.4: mRNA
variant 3) [2] or 1b (NM_001282163.1: mRNA variant 4)
[3] are spliced to exon 2 and contain the start sequenceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tains intron 1 (exon 1b1) (alternative mRNA variant 4) [4].
Subsequently, two additional long transcripts due to alter-
native splicing of exon II and including exons I to IV have
also been identified (NM_001127899.3: mRNA variant 1
and NM_001127898.3: mRNA variant 2) [5]. Both of these
transcripts carry the ATG start sequence in exon III,
thereby encoding a NH2-terminal extended ClC-5 isoform
consisting of 816 amino acids instead of the canonical
transcript of 746 amino acids.
Although more than 150 different mutations have been
reported within the CLCN5 coding exons, patients with
typical symptoms of Dent disease 1 have been genotyped
by our group and others in whom no mutations could be
detected [6-9]. The presence of many different 5′UTR
ends of CLCN5 mRNA in the kidney highlights the com-
plexity of both the molecular structure and the regula-
tory apparatus of the gene. Moreover, the 5′UTR might
hide Dent disease 1 disease-causing mutations or poly-
morphisms that may influence disease expression. In-
deed, while analysing 30 CLCN5 negative patients our
group identified a nucleotide substitution in the 5′ un-
translated exon 1b1 of one individual which appeared
disease-causing since it was not detected in 471 X nor-
mal chromosomes [10].
The functional significance of these regulatory regions
has not been elucidated. Their differential expression in
the kidney versus other human tissues like brain, skeletal
muscle and the eye has also not been assessed, despite the
potential involvement of these organs in Dent 1 cases [11].
Thus we decided to study this region in depth. Here we re-
port the identification of additional 5′UTR ends of human
CLCN5 cDNA within the kidney, including the presence of
newly identified exons. In total eight exons are now known
to be present in the 5′UTR region of the CLCN5 gene,
giving rise to eleven isoforms. Moreover we succeeded in
extending the 5′ ends of the previously known CLCN5
transcripts to identify new transcription start sites. These
novel CLCN5 mRNA species are demonstrated to be dif-
ferently expressed in kidney and other human tissues.
Methods
RNA ligase-mediated rapid amplification of cDNA
5′ ends PCR
The GeneRacer kit (Invitrogen) was used in accordance
with the manufacturer’s instructions to obtain clones with
the 5′ portion of the human CLCN5 cDNA. In brief, 5 μg
of total human kidney RNA (Stratagene) was treated with
calf intestinal phosphatase to remove 5′ phosphates. This
has no effect on capped full-length mRNA but removes
non-mRNA or truncated mRNA from the ligation re-
action. The sample was then treated with tobacco acid
pyrophosphatase to remove the 5′ mRNA cap structure,
which leaves a 5′ phosphate required for ligation tothe GeneRacer RNA Oligo (5′-CGACUGGAGCACG
AGGACACUGACAUGGACUGAAGGAGUAGAAA-3′).
The GeneRacer RNA Oligo was ligated to the 5′ end of
the decapped mRNA with T4 RNA ligase, which provides
a known priming site for the GeneRacer PCR primers. A
reverse transcription reaction was then performed using
SuperScript III Reverse Transcriptase and the GeneRacer
Oligo dT Primer (5′-GCTGTCAACGATACGCTACG-
TAACGGCATGACAGTG(T)24-3′) provided in the kit.
The CLCN5 5′ cDNA ends were amplified with a touch-
down PCR using a CLCN5 gene specific antisense primer
(rRACE Ex 2), the GeneRacer 5′ primer and Platinum Taq
DNA Polymerase High Fidelity (Invitrogen). Cycling con-
ditions followed the manufacturer’s protocol. After the
successful amplification was confirmed by agarose gel
electrophoresis, a second round of nested PCR ampli-
fication was done as above, except that the GeneRacer 5′
nested primer and the CLCN5 gene specific nested anti-
sense primers were used in place of the GeneRacer 5′ pri-
mer and the CLCN5 rRACE Ex 2 primer, respectively (see
Additional file 1). The PCR products were cloned into
plasmid vector pCR4-TOPO and transformed into com-
petent One Shot TOP10 cells with a TOPO TA clon-
ing kit (Invitrogen) following the supplier’s protocol.
Colonies were analysed by PCR, using vector specific
primers (M13F: 5′-GTAAAACGACGGCCAG-3′; M13R:
5′-CAGGAAACAGCTATGAC-3′). In total, 172 clones
were sequenced using vector specific primers.
Sequencing
The sequence analysis of cDNA clones and of RT/PCR
products was performed using a direct Sanger sequencing
method. The sequencing process included purification of
PCR products using the MinElute PCR Purification Kit
(Qiagen), sequencing via the Big Dye Terminators v1.1
Cycle Sequencing Kit (Applied BioSystems), and final
purification using Centrisep Columns (Princeton Sepa-
ration), all in accordance with operational manuals. Se-
quences were analyzed using an ABI-PRISM 3100 Genetic
Analyzer (Applied BioSystems). To compare CLCN5 5′
UTR cDNAs and coding region with its genomic se-
quences, the NCBI Blast 2 sequence alignment program
was used. The human CLCN5 mRNA (GeneBank acces-
sion number NM_001127899.3; NM_001127898.3; NM_
000084.4; NM_001282163.1 and NM_001272102.1), the
human CLCN5 DNA sequence on chromosome X
(GenBank accession number NG_007159.3) and the
CLCN5 promoter region (GeneBank accession number
AB020597.1) were used for comparison.
Quantitative comparative RT/PCR analysis of CLCN5
mRNA in different human tissues
All patients gave their informed, written consent. Total
RNA from leucocytes of healthy human subjects was
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according to the manufacturer’s instructions. The collec-
tion of the blood samples used in this study was made
with the appropriate approval of the Ethics Committee
of Azienda Ospedaliera of Padova. One μl of RNA was
used for spectrophotometric quantification at 260 and
280 nm using the NanoDrop ND-1000 spectrophoto-
meter (NanoDrop Technologies), and RNA integrity
was checked with the Agilent 2100 bioanalyzer (Agilent
Technologies). Total RNA from human normal tissue
samples (kidney, brain, lung, liver, colon, placenta, testes,
skeletal muscle), and from endothelial cells were pur-
chased from Stratagene.
To analyze the differential expression of CLCN5 gene
5′UTR ends, a different set of primers were designed
(see Additional file 2). The primers Ex I/II F and Ex IV/2
R were the same used by Ludwig et al. [5]. Two hundred
nanograms of total RNA were reverse-transcribed in a
total volume of 20 μl containing 5 mM MgCl2, 1 mM
dNTPs (Roche Diagnostics), 2.5 μM random hexamers
(Applied Biosystems), 1U RNase inhibitor (Applied Bio-
systems), 2.5 MuLV reverse transcriptase (Applied Biosys-
tems) in a buffer of 50 mM KCl, 10 mM Tris HCl pH 8.3.
The reaction was carried out at 42°C for 30 min followed
by 5 min at 99°C. An aliquot (1.5 μl) of RT reaction was
used to amplify all alternative CLCN5 mRNA species in a
final volume of 25 μl containing 1.5, 2 or 3 mM MgCl2,
0.2 mM dNTPs (Roche Diagnostics), 0.4 μM primers, 0.04
U JumpStart Taq (Sigma-Aldrich) in 50 mM KCl, 10 mM
Tris HCl pH 8.3. The amplification profile for each primer
set consisted of an initial denaturation at 95°C for 5 min,
followed by different amplification cycles (45 s at 94°C,
45 s at specific Ta°C, 1 min at 72°C), and an exten-
sion at 72°C for 7 min. PCR conditions are given in
(see Additional file 2).
To quantify the relative expression of each 5′UTR
end, a semiquantitative comparative RT/PCR approach
was performed using GAPDH as a housekeeping gene
[12]. RT/PCR products were analysed by 7% polyacry-
lamide gel electrophoresis followed by silver staining
as previously described [12]. One μl was also analysed
and quantified using the Agilent Bioanalyser technology
(Agilent Technologies). Negative control reactions were
performed without reverse transcriptase during a cDNA
synthesis step to rule out any genomic contamination.
Real-Time PCR of CLCN5 mRNA in the human kidney
Real-Time quantitative polymerase chain reaction was
performed to analyze the expression levels of all the
CLCN5 mRNA species in the human kidney. Changes in
CLCN5 gene mRNA levels were determined by quanti-
tative relative Real-Time PCR with the iCycler Termal
Cycler (Bio-Rad). The reaction was carried out in a final
volume of 25 μl containing 1 μl of RT reaction, 1× iQSYBR Green supermix (BioRad) and 0.3 μM of specific
primers for 5′UTR exons. To avoid genomic contami-
nation, primers spanning exon boundaries were con-
structed. It was not possible to design primer pairs
specific for all isoforms, and for this reason isoforms
containing exon IIa were quantified together as a group,
as were isoforms containing exon IIb (see Additional
file 3). Samples were loaded in triplicate, 25 μl/well, in
96-well plates (Biorad). Negative control reactions were
performed to rule out any contamination.
The thermal cycling profile was the same for each pri-
mer set and consisted of an initial denaturation at 95°C
for 5 min, followed by 45 amplification cycles of 10 s at
95°C and 45 s at 66°C, followed by 1 cycle at 60°C for
1 min. Melting curve analysis consisted of 80 cycles at
60°C for 10 s and was used to confirm the specificity of
the amplification products. GAPDH was the housekeep-
ing gene used as an internal primer control. A positive
cDNA control was also used as reference (the isoform
A, the most abundantly expressed).
The relative expression of each 5′ UTR isoform was
compared to GAPDH expression calculating the ΔCt
value of expression as follows: Ct isoform – Ct GAPDH.




html) [14], NetGene2 (http://www.cbs.dtu.dk/services/
NetGene2/) [15], and GeneSplicer (http://www.cbcb.
umd.edu/software/GeneSplicer/gene_spl.shtml) [16] pro-
grams were used to identify potential splice sites.
Amino acid sequences were subjected to computational
analysis with the ORF Finder program (http://www.ncbi.
nlm.nih.gov/projects/gorf/).
The online tool Human Splicing Finder version 2.4.1
(http://www.umd.be/HSF/HSF.html) was used to identify
splicing motifs in our human sequence of interest [17].
The web server mRNAfold (http://rna.tbi.univie.ac.at/cgi-
bin/RNAfold.cgi) was used to predict the pre-mRNA sec-
ondary structure [18,19].
The analysis of the CLCN5 promoter region was per-
formed using the ENCODE (Encyclopedia of DNA Ele-
ments) project [20] data in the UCSC Genome Browser
for defining the transcriptional regulatory regions.
Results
Structure of CLCN5 5′UTR region
RACE analysis of CLCN5 5′ cDNA ends in the human
kidney detected eleven transcripts initiating at three dif-
ferent nucleotides: - 2407, - 1426 in respect to the ATG
initiation codon in exon 2, and at - 660 in respect to the
ATG initiation codon in exon III. Analysis not only con-
firmed the presence of previously identified UTR isoforms
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identified new transcription start sites. A transcript initiat-
ing at nucleotide - 2407 corresponds to mRNA variant 3,
but is extended a further 41 bp in respect to the +1 origin
reported in the NCBI reference sequence NM_000084.4.
This result is in agreement with in silico analysis con-
ducted with NNSPLICE, NetGene2, or GENESPLICER
[14-16]. All of the tested programs predict a consensus se-
quence (5′-tcccag^GC-3′) containing the conserved motif
“AG” at 41 bp upstream of exon 1a, which constitutes a
potential acceptor splice site of high strength. These same
programs do not identify the previously described ac-
ceptor site.
We were also able to confirm the presence of the al-
ternative mRNA variant 4, albeit longer than earlier de-
scribed by Forino et al. [4]. It retains intron 1b and
consists of an extended exon 1b (exon 1b1) with a new
putative transcription start site located at nucleotide -
1426 in intron 1a, 1001 nt upstream of the beginning of
exon 1b, and is 1379 bp long. In silico analysis also de-
tected a candidate acceptor splice site that contains the
conserved motif “AG”, (5′-ctacag^AT-3′) corresponding
to the beginning of the transcript identified by RACE
analysis (Figure 1).
We also extended the 5′ end of mRNA variant 4,
870 nt further in respect to the +1 origin reported in the
NCBI reference sequence NM_001282163.1, but it was
not possible to obtain the full length cDNA. Therefore
we hypothesized that the mRNA variant 4 and the alter-
native mRNA variant 4 have the same transcription start
site differing only regarding the absence/presence of in-
tron 1b (Figure 1).
We confirmed the presence of the mRNA variants 1
and 2 identified by Ludwig et al. [5] with both alterna-
tively spliced exons IIa and IIb which, according to the
NCBI reference sequences NM_001127899.3 and NM_
001127898.3, contain the transcriptional start site atFigure 1 Characterization of the CLCN5 5′UTR variant 4 and alternativ
putative transcriptional start site of alternative variant 4, located at intron 1
Fisher et al. (2). For variant 4 it was not been possible to obtain the full len
start site and differ only regarding the absence/presence of intron 1b. Colonucleotide - 660 in respect to the ATG initiation codon
in exon III.
RACE analysis detected six new 5′UTR ends of hu-
man CLCN5 cDNA. One isoform consisted of a new
287 bp exon newly named exon c, located within intron
1a according to the classical 5′UTR structure, represent-
ing an alternative splicing of the mRNA alternative vari-
ant 4 if one considers the new structure of exon 1b1
resulting from our RACE PCR analysis. Exon c contains
a palindromic region of 28 nucleotides and, as a result of
5′ alternative splicing, originates two different mRNAs
containing an exon c.1 of 102 bp (5′-TT^gtaagt-3′) and
exon c (5′-AG^gttggt-3′), respectively (Figure 2). We
called these variants 6 and 7. As observed from analysis
of splice sites and from consensus values calculated with
the Shapiro and Senapathy matrices [21], both donor
splice sites have similar consensus values (c.1 79.4, and
c 79.2), and have similar strength, and likely compete
for splicing factors.
Due to alternative splicing of exon II, four new long
transcripts were detected, two of them containing the
exon VI (variant 8 and 9), and the other two containing
exon V and VI (variant 10 and 11). Both new exons V
and VI (131 bp and 194 bp long, respectively) are lo-
cated 7820 bp and 11977 bp downstream of the exon IV
respectively (Figure 3). Bioinformatic tools identified the
acceptor (5′-tgtcag^AG-3′) and donor (5′-AG^gtaagc-
3′) splice sites upstream and downstream of the exon
VI. These tools identified only the donor splice site (5′-
AG^gtatgt-3′) for exon V.
With our experiments we were not able to identify the
mRNA variant 5 (NM_001272102.1). From these results
we can conclude that the human CLCN5 gene comprises
at least 20 exons, eight of them in the 5′UTR region,
with transcription initiating from at least three different
start sites. As a result of 5′ alternative splicing in some
exons, 11 different mRNAs are generated (Figure 4). Thee variant 4 by RACE PCR and sequencing. + 1 indicates the
a, 1001 nt upstream of the first nucleotide of exon 1b described by
gth cDNA but probably the two variants have the same transcription
ured boxes represent exons and open boxes represent introns.
Figure 2 Characterization of the CLCN5 5′UTR variants 6 and 7 by RACE PCR and sequencing. + 1, which is located at intron 1a, indicates
the putative mRNA variant 7 transcriptional start site that is the same of alternative variant 4. Exon c of 287 bp after 5’ alternative splicing
originates two different mRNAs containing an exon c.1 of 102 bp (variant 6) and exon c of 287 bp (variant 7). Coloured boxes represent exons
and open boxes represent introns.
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known CLCN5 transcripts (type 3, 4 and alternative 4)
and of the newly identified CLCN5 5′UTR variants (types
6-11) are given in Additional file 4.
Expression of CLCN5 5′UTR ends in different human
tissues
Healthy human tissues (kidney, brain, lung, liver, colon,
placenta, testes, skeletal muscle, endothelial cells and pe-
ripheral leucocytes) from normal individuals were used
to evaluate the presence and the expression of the diffe-
rent CLCN5 transcripts. Both the translated region com-
mon to all isoforms (exons 3-6) and the 5′UTR ends
were analyzed. Quantitative comparative RT/PCR analysisFigure 3 Characterization of the new CLCN5 5′UTR long transcripts by
already described exons I-IV and the new exons V and VI (variants 8-11) (13
downstream of the exon IV respectively . + 1 indicates the putative transcr
initiation codon in exon III. Coloured boxes represent exons and open boxdetected CLCN5mRNA in all investigated tissues (Table 1,
and Additional file 5).
Using primers specific for each 5′UTR isoform we
demonstrated that some are not present in all tissues,
and that the kidney is the unique tissue in which all iso-
forms are expressed (Table 1). Analysis of the distribu-
tion of CLCN5 5′UTR ends revealed that the already
known mRNA variants 1-4 and alternative variant 4 are
expressed in all tissues with variable levels: the mRNA
variant 3 is the most abundant in all tissues except the
lung, and the mRNA variant 4 is the less abundant in all
tissues except the colon. mRNA variants 1 and 2 are also
present in all tissues, and the transcript containing exon
IIa is much more abundant than that with exon IIb.RACE PCR and sequencing. The four long transcripts contain the
1 bp and 194 bp long, respectively), located 7820 bp and 11977 bp
iptional start site located at nucleotide - 660 in respect to the ATG
es represent introns.
Figure 4 Genomic organization of CLCN5 5′UTR region. The CLCN5 5’ UTR region consists of 8 different 5’ alternatively used exons, some of
this, remains untranslated. As a result of 5’ alternative splicing (represented by two vertical bars) in exons II and 1b, 11 different mRNAs are
generated. Transcription initiates from three different start sites (represented by an arrow) and there are three translation start sites (represented
by an inverted triangle). Coloured boxes represent exons and the connecting lines between boxes the introns.
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erogeneous between different tissue samples: both are
expressed in the kidney, only variant 6 was expressed in
liver and lung, while neither variant 7 was present in the
remaining tissues. The variant 7 appeared specific to theTable 1 Results of RT/PCR analysis of 5′ CLCN5 mRNA variants
Tissue
1 2 3 4 Alternative 4
Liver +++ +/− +++ - ++
Lung +++ +/− + - ++
Placenta +++ + ++ - +
Testes +++ + +++ - +++
Skeletal muscle +++ + ++ - ++
Brain ++ + +++ - +++
Colon +++ + +++ + +++
Endothelial cells +++ +/− ++ - +
Kidney +++ + +++ - +++
Leucocytes ++ + ++ - ++
The table reports the presence/absence of all identified variants and their relative ekidney and was absent from all other tissues. The four
new long 5′UTR isoforms containing exon VI or exon V
plus exon VI also have variable expression levels be-
tween tissues. The transcript with exon VI (variants 8
and 9) is present in almost all sites except liver, lung andmRNA variants
6 7 8 9 10 11 CLCN5
Common
Region
+ - - - - - +++
+ - - - - ++
- - +++ - - - +
- - +++ - +++ - +++
- - +++ - - - +++
- - +++ - - - ++
- - ++ ++ + + +++
- - - - - - +
++ +++ +++ ++ ++ + +++
- - +++ - - - ++
xpression in different human tissues and cells.
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and VI (variants 10 and 11) is expressed only in kidney,
colon and in testes. In both cases the mRNAs with exon
IIa are much more abundant than that with exon IIb
(Table 1).
In summary, the different 5′UTR ends have variable
expression levels from tissue to tissue. The tissues that
are most similar regarding the isoform expression,
both in terms of abundance and expression pattern,
are kidney, colon and testis. The mRNA variants 3,2,
the alternative variant 4 and variant 7 appear to be
the most abundant in these 3 sites.
Real-Time PCR quantification of the CLCN5 mRNA species
in the human kidney
Finally, the levels of all 5′UTR isoforms we identified
were quantified in human kidney tissue using Real Time
PCR. The isoforms have very different expression levels:
the mRNA variant 3, which was used as a calibrator to
calculate the relative abundance of other isoforms, is the
most abundant; all the mRNA variants containing exon
IIa (variant 2, 8 and 10) and variant 7 have slightly lower
levels (Figure 5).
In general, the results of Real-Time experiments were
in agreement with those observed by RACE analysis.
In fact out of 172 cloned 5′ RACE fragments, 77 (45%)
contained type 3 mRNA species, 46 (27%) contained
type 7, 34 (20%) were type 2, and 6 (3.5%) were alter-
native type 4.
Discussion
Our results show that the human CLCN5 gene
comprises at least 20 exons, eight of them being in
the 5′UTR region, with transcription initiating from at
least three different start sites. As a result of 5′ alternative
splicing in some exons, 11 different mRNAs are generated.
Our findings highlight the structural complexity of theFigure 5 Real time PCR quantification of CLCN5 isoforms in the huma
isoforms were quantified using the mRNA variant 3, the most abundantly e
values in logarithmic scale.CLCN5 5′UTR region in renal and extrarenal tissues,
and suggest that this region is likely involved in
ClC-5 expression and Dent disease pathogenesis.
Although some authors [5,8] have tested the pro-
moter region in their patients without detecting vari-
ants, the deeper characterization obtained by our
study should allow to explore regions of the gene
never analyzed before for searching possible rare
variants that may act as disease-causing mutations
or modifier alleles.
To further characterize the functional organization of
the gene, the 5′-flanking region of exons 1a, 1b1 and I
were analyzed for possible promoter regions and
transcription factor binding sites. ENCODE project data,
aimed to delineate all of the functional elements
encoded in the human genome sequence including the
mapping of histone modifications, the transcription
factor (TF) binding sites by chromatin immunoprecipi-
tation (ChIP), and the transcriptional regulatory
regions, were used. Thus the Transcription track, the
Overlayed H3K4Me1 and Overlayed H3K27Ac tracks,
the DNase Clusters, and the Txn Factor ChIP tracks
were considered. These tracks complement each other
and together can shed much light on regulatory
DNA [20].
The results suggest that 3 functional promoters are
present in the CLCN5 gene of different strength, origi-
nating all isoforms with varying efficiency. Strong
promoters are present upstream of exon 1a and exon I,
and indeed variant 3 and variants 1 and 2 are the mRNA
species most expressed in the kidney (Figure 5). Both
promoters lack characteristic features of eukaryotic
promoters, but instead contain consensus binding sites
for transcription factors. GATA1 and GATA2 factor
binding sites and consensus binding sites for diffe-
rent transcription factors including E2F1 (transcrip-
tion factor 1), ZNF263 (zinc finger protein 263),n kidney. Data were normalized to GAPDH housekeeping gene; the
xpressed, as a reference value (10^0). The y- axis reports the expression
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mobility group nucleosomal binding domain 3), USF1
(upstream transcription factor 1) and Ini1 (RING
finger-like protein Ini1) are present for mRNA variants
1 and 2. For mRNA variant 3 the identified binding
sites for the transcription factors are USF1, USF2
(upstream transcription factor 2, c-fos interacting),
KAP1 (kinesin-ii-associated protein), and CTCF
(CCCTC-binding factor). All these transcription
factors were identified in a kidney cell line (HEK293).
A weaker promoter appears to control the expression
of mRNA variant 4, alternative variant 4 and variants 6
and 7. This promoter contains consensus binding sites
for some transcription factors such as FOXA2 (forkhead
box A2) and SETDB1 (SET domain, bifurcated 1). For
all promoters the specific region containing the tran-
scription factor binding sites overlap with a region that
is DNaseI sensitive. At the functional level, DNase
hypersensitivity suggests that a region is very likely to
be regulatory in nature, and promoters are particularly
DNase sensitive.
The data from ENCODE project did not identify
sites for the transcription factor HNF1α. Instead, in
silico analysis conducted by Tanaka et al. [22] had
revealed numerous HNF1α binding sites in the 5′
regulatory sequences of both mouse and human
Clcn5/CLCN5 gene. The transactivation of the Clcn5/
CLCN5 promoter by HNF1α was verified in vitro, and
the binding of HNF1α to the Clcn5 promoter in vivo
was confirmed by chromatin immunoprecipitation in
mouse kidney [22].
The mRNA variant 4, the alternative variant 4 and
variants 6 and 7 share the same transcription start site
but have different lengths that depend on which donor
site is used. They are probably generated, with differen-
tial efficiency, by multiple alternative splicing occurring
at the 5′of a single exon. This type of exon commonly
originates from ancestral constitutive exons that, follo-
wing mutation/s inside the exon or along the flanking
intron, result in the creation of new alternative splice
sites that compete with the ancient one for splice site
selection [23].
In the case of variants 6 and 7, the two alternative 5′
splicing sites in exon c have similar strength and so
regulation is essential. It seems that the delicate balance
between cis acting elements-enhancer (ESE) splicing
regulatory elements (ESR) and silencers (ESS) located
immediately upstream of each splice site is probably the
major factor governing the level of each site usage in
splicing [23,24]. In order to determine if this is the case,
bioinformatic analysis, using the Human Splicing Finder
version 2.4.1 program [17] was performed. The results
of this analysis demonstrated that two ESE, two ESR and
six ESS are present in the first 15 nt upstream of thedonor splice site of exon c.1. Upstream of the donor
splice site of exon c eight ESE, three ESR and five ESS
are present. Therefore, although both sites have a similar
strength, a higher density of ESE-ESR and lower density
of ESS upstream of the exon c promote use of this splice
site. Consistent with this observation, the expression
levels of variant 7 are higher than those of variant 6
(Figure 5).
In the case of mRNA variant 4, the donor splice site of
exon 1b has a higher strength (value of 82.4) and there-
fore is favored. This isoform also contains 10ESE, 2 ESR
and 6 ESS. However this is not in agreement with our
experimental results because this isoform is barely
expressed. Alternative variant 4, whose level of expres-
sion follows that of mRNA variant 3 of mRNA variants
1, 2 and 8-11, is characterized by the presence of exon
1b and the retention of intron 1b (exon 1b1) that,
contrary to what usually happens, has not been removed
during the processing of the primary transcript to
mature messenger. Most likely other factors play an
important role in the regulation of its transcription
levels. Exon 1b1 could represent the ancestral consti-
tutive exon from which all other exons (1b, c and c.1)
originated (Figure 4). This exon is, in fact, usually present
as the main product in respect to the others (Figure 5).
The GC content around splice sites is closely associ-
ated with the splice site usage [18,19,25]. We considered
a region of 141 nucleotides surrounding the donors
splice sites of exons c.1, c and 1b (70 nucleotides
upstream and downstream of the splice site). It was
possible to see that the highest GC content (11 GC) is in
the donor splice site of exon c, exon c.1 (7 GC), and
exon 1b (5 GC).
The web server mRNAfold was then used to predict
the pre-mRNA secondary structure via calculation of
minimum free energy [18,19]. It has been reported that
local RNA secondary structures affect splice site selec-
tion, the splicing sites closest to the start transcription
site forming more stable structures than those located in
more central RNA locations [18,19]. The minimum free
energy calculated by the software was -44.70, -38.84
and -30.70 kcal/mol for the donor splice sites down-
stream of the exons c, c1 and 1b, respectively. Both the
evaluation of GC content and the calculation of free
energy once again are in agreement with the results we
obtained from the expression study. In fact, the expression
level of isoform containing exon c is higher than those
containing exon c.1 and 1b (Figure 5).
To conclude our characterization, we proceeded with
the open reading frame analysis using the ORF Finder
program. ORF analysis revealed that the mRNA variants
3, 6, 7 and alternative variant 4, as well as variants 8-11
encode for the canonical ClC-5 protein of 746 amino
acids while variant 4, and variants 1-2 for a protein with
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It is of note that the presence in the long transcripts of
exon VI and/or V stabilizes the initiation of translation
to the ATG in exon 2 and do not add, to the protein,
additional amino acids. This is the most common situ-
ation among most genes that have alternative promoters
and, while not generating different protein isoforms,
have mRNA variants which differ in the transcription
pattern and in translation efficiency.
The ClC-5 translated region was expressed in all human
tissues examined. Our results are in agreement with what
reported by Steinmeyer et al. [26] who demonstrated in
the mouse that ClC-5 was predominantly expressed in the
kidney but also observed in brain, liver, lung, and testis.
Unlike Ludwig et al. [5], but in agreement with Ramos-
Trujillo et al. [27] we demonstrated that ClC-5 is present
in the human liver, brain and skeletal muscle.
On the contrary not all the 5′UTR isoforms are
expressed in the various tissues. mRNA variants type 3,
2, 7 and alternative variant 4 appear to be the most
abundant in the human kidney. 5′UTR exons that are
commonly present among expressed isoforms are candi-
dates for mutation analysis of Dent disease patients
without genetic variation in the CLCN5 coding region.
Polymorphisms or rare variants might also reside in
these regions that acting as modifier alleles and might
explain the phenotypic heterogeneity of Dent disease not
only in Dent disease 1 but also in Dent disease 2. We have
demonstrated, in fact, that variants in both OCRL and
CLCN5 genes may act in concert in determining Dent
disease phenotype variability [28].
Despite widespread expression of ClC-5, the Dent
disease 1 phenotype is largely renal. Different 5′UTR
ends present in various tissues may serve to differently
regulate gene expression in response to physiological
and pathological stimuli through mechanisms involving
not only transcription but also translation efficiency. It is
known, in fact, that the 5′UTR region has several roles
in translational efficiency and translation inhibition
probably through the interaction with the ribosome
and specific DNA binding proteins or through some ele-
ments contained in non coding regions. So, it is possible
that CLCN5 mRNA levels do not correspond to ClC-5
protein level and actual ClC-5 functions.
Also of note is the presence of ClC-5 in the human
brain and skeletal muscle. Although CNS and muscle
impairment is common in Lowe syndrome, it has not
been described in Dent disease 1 [11]. We recently evalu-
ated a patient carrying a CLCN5 mutation whose clinical
symptoms suggested a Dent 2 phenotype or a mild Lowe
phenotype (unpublished). Our findings point to the possi-
bility that certain Dent cases with CLCN5 disease-causing
mutations might manifest extrarenal symptoms or a mild
Lowe phenotype.The tissues that are most similar, both in terms of
abundance and expression pattern of CLCN5 UTR
isoforms are kidney, colon and testis. It is known that in
rats and pigs ClC-5 is expressed in intestinal tissues that
have endocytotic machinery [29,30]. As in renal
proximal tubular and intercalated collecting duct cells,
intestinal and colon epithelial cell ClC-5 is predomi-
nantly if not exclusively intracellular, located in densely
packed endocytotic vesicles in rats [29]. Some authors
have evaluated the role of ClC-5 in intestinal calcium
absorption by directly regulating the expression of
calcium transport proteins, such as TRPV 6 [30-33].
Although in humans the intestinal calcium absorption
takes place mainly in small intestine, our data, albeit
indirectly, can support the hypothesis that in Dent
disease hypercalciuria may be due to increased intestinal
absorption of calcium rather than decreased tubular
re-absorption.
No phenotype associated with testicular dysfunction
has been described so far in Dent disease patients. Fu-
ture studies might be warranted to explore the possible
role of ClC-5 in male infertility and to determine testicu-
lar function in Dent disease 1 patients, analogous to the
role of the CFTR gene in male infertility [34].Conclusions
Our results confirm the structural complexity of CLCN5
5′UTR region. The presence of many different CLCN5
5′UTR ends as well as the selective use of alternative
promoters can affect if/when and how the transcript is
translated, by binding to different transcription factors
and regulating translation efficiency. The meaning of
this complexity, characterized by the presence of several
CLCN5 isoforms differentially-regulated in a tissue spe-
cific manner, likely in relation to physiological and/or
pathological conditions, remains to be clarified. This com-
plexity might explain aspects of the Dent disease pheno-
type and pathogenesis, and might obscure disease causing
mutations or polymorphisms that influence disease
expression. It will be interesting to analyze renal CLCN5
isoforms and their expression levels in both normal and
pathological conditions to identify and understand their
physiologic and pathophysiologic roles.Additional files
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